Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
R-CHOEP14x6+HD-AraC+HD-Mtx · 1 trial · 1 indication
Interval between the registration date and the date of documented progression or lack of response, first relapse, death for any reason or discontinuation/change of therapy because of toxicity, whichever occurs first. Otherwise, patients will be censored at the last date they were known to be alive. For patients not responding at any time point on study treatment, TTF is defined as 1 day.
| Arm | Type | Description |
|---|---|---|
| Chemoimmunotherapy | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| R-CHOEP14x6+HD-AraC+HD-Mtx | DRUG | rituximab 375 mg/m2 day 1 cyclophosphamide 750 mg/m2 day 1 doxorubicin 50 mg/m2 day 1 vincristine 1.4 mg/m2 day 1 etoposide 100mg/m2 days 1,2,3 Prednison 100 mg days 1,2,3,4,5 cycle repeated six times every two weeks followed by HD-AraC 3g/m2x4 and HD-mtx 3 g/m2 HD-AraC 3g/m2x4 times every 12 h |
Inclusion Criteria: 1. Age ≥ 18 - \< 65 years. 2. Histology verified according to the WHO classification and with CD20 positivity by immunhistochemistry or flow cytometry: * Diffuse large B-cell lymphomas with subgroups except posttransplantation-, Burkitt-like- and primary CNS lymphomas and ca...
R-CHOEP14x6+HD-AraC+HD-Mtx is an investigational combination chemotherapy regimen being studied for the treatment of Diffuse Large B-Cell Lymphoma (DLBCL). It is currently in Phase 2 clinical development and is not approved by regulatory authorities.
R-CHOEP14x6+HD-AraC+HD-Mtx is being developed by Amgen Inc. (NASDAQ: AMGN). The company is conducting clinical trials to evaluate this regimen in patients with Diffuse Large B-Cell Lymphoma.
R-CHOEP14x6+HD-AraC+HD-Mtx is in Phase 2 clinical development. It is an investigational regimen, meaning it has not been approved by the FDA or other regulatory agencies and is still being studied for safety and efficacy.
R-CHOEP14x6+HD-AraC+HD-Mtx is associated with one completed Phase 2 clinical trial, NCT01502982, titled 'Dose Dense Chemotherapy and Rituximab for Young High Risk Diffuse Large B-Cell Lymphoma Patients (CRY-04)'. The trial enrolled 160 participants across Denmark, Finland, Norway, and Sweden.
No, R-CHOEP14x6+HD-AraC+HD-Mtx is not FDA approved. It is an investigational combination regimen currently in Phase 2 clinical trials for Diffuse Large B-Cell Lymphoma. Approval status has not been granted, and it remains under clinical investigation.